The company's line of diagnostic and therapeutic products for diabetics includes BYDUREON, a weekly diabetes treatment that improves glycemic control in adult patients with type 2 diabetes. Amylin Pharmaceuticals is dedicated to challenging science and changing lives, with employees who think outside the box and constantly strive to find newer and better ways to treat diabetes. As a wholly owned subsidiary of Bristol-Myers Squibb, the company is building an exciting new franchise in the treatment of metabolic disease and a pipeline of possibilities for future healthcare solutions.